Compare IBOC & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBOC | APGE |
|---|---|---|
| Founded | 1966 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | 1995 | 2023 |
| Metric | IBOC | APGE |
|---|---|---|
| Price | $71.23 | $85.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $87.00 | ★ $109.67 |
| AVG Volume (30 Days) | 316.6K | ★ 659.4K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 0.76 | N/A |
| EPS | ★ 6.62 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.00 | $34.34 |
| 52 Week High | $75.44 | $95.32 |
| Indicator | IBOC | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 53.68 |
| Support Level | $67.24 | $73.06 |
| Resistance Level | $72.77 | $95.32 |
| Average True Range (ATR) | 1.34 | 3.50 |
| MACD | 0.08 | -0.46 |
| Stochastic Oscillator | 64.92 | 31.19 |
International Bancshares Corp is a registered multibank financial holding company providing a diversified range of commercial and retail banking services in its main banking and branch facilities located in north, south, central, and southeast Texas and the State of Oklahoma.. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.